Clinical Trial Update: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy [Phase 1]

View source ↗

Summary

Phase 1 study of IBI322 in patients with hematologic malignancies has completed, reporting on safety, tolerability and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• IBI322

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Hematologic Malignancy | Phase 1 | Status: COMPLETED